

Corporate Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-19 Tel: +91 11 47589500 (30 Lines), 262218111/26418182 E-Mail : info@shivalikrasayan.com Website: www.shivalikrasayan.com CIN: L24237UR1979PLC005041

Ref: STEX/DEV Report/2023-24 Date- 12.02.2024

**BSE Limited** 

Phiroze Jeejeebhoy Towers, Dalal Street Mumbai- 400001

Scrip Code-539148

**National Stock Exchange of India Ltd** 

Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051

Symbol- SHIVALIK

Sub: Statement for Deviation(s) or Variation(s) under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended December 31, 2023

Dear Sir/Madam,

Pursuant to Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/ 162/2019 dated December 24, 2019; please find enclosed herewith Statement of deviation(s) or variation(s) of funds raised through preferential issue by the Company in the specified format, for the quarter ended December 31, 2023. The same has been reviewed by the Audit Committee of the Company on 12.02.2024.

This for your information and records

Thanking you,

Yours faithfully

For Shivalik Rasayan Limited

Parul Choudhary Company Secretary & Compliance Officer ACS- 34854

Statement of Deviation / Variation in utilization of funds raised						
Name of listed entity						
Mode of Fund Raising	Preferential					
	Issues					
Date of Raising Funds	29.09.2023					
Amount Raised	60.22 CR	1				
Report filed for Quarter ended	31.12.2023	1				
Monitoring Agency	applicable/					
	not applicable					
Monitoring Agency Name, if applicable						
Is there a Deviation / Variation in use of funds raised	<del>Yes</del> / No					
If yes, whether the same is pursuant to change in terms of a contract	NA					
or objects, which was approved						
by the shareholders						
If Yes, Date of shareholder Approval	NA					
Explanation for the Deviation / Variation	NA					
Comments of the Audit Committee after review	There is no					
	deviation/varia					
	tion in the utilization					
	of funds					
Comments of the auditors, if any	NA					
Objects for which funds have been raised and where	NA					
there has been a deviation, in the following table						
Original Object	Modified	Original	Modified	Funds	Amount of	Remarks ifany
,	Object, if any	Allocation	allocation	Utilized	Deviation/Va	
			if any		riation forthe	
					quarter	
					according to	
					applicable	
The Company intende to utilize the granted writed through the investment	Not Applicable	E0 03 CB	Not	20 00 CD	object	
The Company intends to utilize the proceeds raised through the issue ("Issue Proceeds") towards the following objects:	not Applicable	DU.UZ CK	Applicable	28.89 CR	Not Applicable	
<ol> <li>For creating a separate facility in its existing Active Pharmaceutical</li> </ol>						
Ingredient (API) plant at Plot No. D-2/CH/41/A, GIDC Industrial						
Estate, Dahej-II, Pin-392140, Distt. Bharuch (Gujarat) to manufacture						
Diabetology and Cardiovascular API's for Domestic Market.						

2. For Working capital requirements of the Co	mpany.									
3. For General Corporate Purpose										
Deviation or variation could mean:										
(a) Deviation in the objects or purposes for which the funds have been raised or										
(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or										
(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc										
Signature										
Name of Signatory	Parul Choudhary	Parul Choudhary								
Designation		Company Secretary & Compliance								
	Officer	Officer								